ID   GTL16R1
AC   CVCL_VS67
SY   GTL16 R1
DR   cancercelllines; CVCL_VS67
DR   GEO; GSM686016
DR   GEO; GSM686035
DR   GEO; GSM686036
DR   Progenetix; CVCL_VS67
DR   Wikidata; Q93935412
RX   PubMed=22745804;
CC   Population: Japanese.
CC   Selected for resistance to: ChEBI; CHEBI_91425; 2-[4-[3-(6-quinolinylmethyl)-5-triazolo[4,5-b]pyrazinyl]-1-pyrazolyl]ethanol (PF-04217903).
CC   Sequence variation: Gene fusion; HGNC; HGNC:1097; BRAF + HGNC; HGNC:30646; SND1; Name(s)=SND1-BRAF (PubMed=22745804).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_7668 ! GTL-16
SX   Female
AG   62Y
CA   Cancer cell line
DT   Created: 25-02-19; Last updated: 10-04-25; Version: 12
//
RX   PubMed=22745804; DOI=10.1371/journal.pone.0039653; PMCID=PMC3382171;
RA   Lee, Nathan V.
RA   Lira, Maruja E.
RA   Pavlicek, Adam
RA   Ye, Jing-Jing
RA   Buckman, Dana
RA   Bagrodia, Shubha
RA   Srinivasa, Sreesha P.
RA   Zhao, Yong-Jun
RA   Aparicio, Samuel
RA   Rejto, Paul A.
RA   Christensen, James Gail
RA   Ching, Keith A.
RT   "A novel SND1-BRAF fusion confers resistance to c-Met inhibitor
RT   PF-04217903 in GTL16 cells through MAPK activation.";
RL   PLoS ONE 7:e39653.1-e39653.12(2012).
//